Scilex Holding (SCLX) Provides Certain Preliminary Q3 Results

Go back to Scilex Holding (SCLX) Provides Certain Preliminary Q3 Results

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024

October 8, 2024 1:58 PM EDT

ZTlido net sales for the quarter ended September 30, 2024 were in the range of $11.0 million to $13.0 million, compared to $10.1 million for the same period last year, representing growth in the range of approximately 9% to 29%.Total product net sales for the quarter ended September 30, 2024 were in the range of $12.0 million to $14.0 million, compared to $10.1 million for the same period last year, representing growth in the range of approximately 19% to 39%.

PALO ALTO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or the Company), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management... More